Weekly Biotech Catalysts
Every Sunday: the coming week of FDA decision dates, Phase 2 and 3 trial completions and earnings, plus the past week of delays, discontinuations, FDA decisions and new timelines from SEC filings.
Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jun 28–Jul 5, 2026)
Here’s what’s on the biotech calendar for June 28–July 5: 2 FDA decision dates, 15 trial catalysts, and 0 earnings reports from tracked companies. 💊 FDA Decisions (PDUFA Dates) Date Ticker Drug Indication Type 2026-06-29 UNCY — hyperphosphatemia in patients NDA 2026-06-30 VRDN — patients with TED BLA 📡 Run-up Radar Highlights Stocks entering the […]
Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jun 21–Jun 28, 2026)
Here’s what’s on the biotech calendar for June 21–June 28: 0 FDA decision dates, 0 trial catalysts, and 0 earnings reports from tracked companies. 📡 Run-up Radar Highlights Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature): UNCY — NDA in 8 days, score 84/100 CELC — NDA in […]
Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jun 14–Jun 21, 2026)
One FDA decision date falls in this week: ACHV’s NDA for nicotine dependence, with a June 20 target date. On the Run-up Radar, UNCY’s NDA decision is 15 days out, and IBRX and AXSM have trial milestones in 17 days. TNGX was last week’s biggest biotech gainer, up 53%. 💊 FDA Decisions (PDUFA Dates) Date […]
Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jun 10–Jun 17, 2026)
A quiet week on the trial calendar. On the Run-up Radar, UNCY leads with an FDA decision on its NDA 19 days out, followed by trial milestones for ADCT and IBRX about three weeks away. Last week’s biggest biotech gainer was TNGX, up 53% on 6.5 times its average volume. 📡 Run-up Radar Highlights Stocks […]